Belatacept in kidney transplant patients with systemic lupus erythematosus. Issue 1 (22nd December 2019)

• Record Type: Journal Article
• Authors: Carrión-Barberà, Irene; Fajardo, Melissa; Danias, George; Tsapepas, Demetra; Gartshteyn, Yevgeniya; Fernandez, Hilda; Askanase, Anca
• Is Part Of: Lupus science & medicine. Volume 6:Issue 1(2019)
• Publication Date: 2019-12-22
• Subjects: autoimmune diseases -- lupus nephritis -- systemic lupus erythematosus -- Treatment; Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1136/lupus-2019-000355
• Languages: English
• ISSNs: 2398-8851

Abstract

Abstract : Objectives: Lupus nephritis (LN) requires renal replacement therapy in 10%–30% of patients. About 30% of these patients receive a kidney transplant. Belatacept is a second-generation, selective, T-cell co-stimulator blocker (inhibits cytotoxic, T-lymphocyte antigen 4, CTLA-4) used as an alternative to calcineurin inhibitors (CNI) for maintenance regimens after kidney transplantation. The pathogenic relevance of CTLA-4 inhibition and the favourable cardiovascular profile of belatacept make it an attractive therapeutic option in systemic lupus erythematosus (SLE). Intravenous administration of belatacept ensures therapeutic adherence. Methods: This retrospective, single-centre study evaluates the outcomes of LN kidney transplant recipients treated with belatacept for reasons not related to SLE at the Columbia University Lupus and Renal Transplant Cohort. Results: Belatacept was started in six patients on CNI regimens at 15.5±17.1 months following transplantation for LN. In five patients, creatinine levels stabilised 6 months after belatacept, one returned to haemodialysis due to CNI toxicity and pyelonephritis and one relisted for a kidney transplant following acute cellular rejection and cortical necrosis. Five patients are followed for extrarenal lupus; no extrarenal manifestations were documented in the other two patients. Data on SLE disease activity pre-belatacept and post-belatacept were available and scored in three patients using the SLE Disease Activity Index Glucocorticosteroid Index (SLEDAI-2KG), which accounts for clinical and laboratory manifestations, as well as steroid dose. Mean SLEDAI-2KG decreased from 13 to 7.6. Conclusion: Belatacept in LN kidney transplant recipients may decrease extrarenal manifestations, attenuate CNI toxicity and stabilise allograft function, providing a better alternative to CNI regimens. Furthermore, these data suggest that belatacept, although initiated for reasons not related to SLE, might have a beneficial effect in SLE.